Fact checked by Nick Blackmer Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Novo Nordisk’s (NVO) semaglutide is a GLP-1 weight loss drug marketed as three separate brand name medications, Ozempic, Wegovy, and Rybelsus. Novo’s Wegovy competes with Eli Lilly’s (LLY) Zepbound.

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Additionally, Lilly CEO David Ricks said the drugmaker will start testing its GLP-1 medications as treatments for alcohol and ...